NCT00404092View on ClinicalTrials.gov

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Invasive Aspergillosis
Interventions
DRUG

caspofungin

i.v.

Trial Locations (4)

3000

University Hospital Gasthuisberg, Leuven

12200

Charité - Campus Benjamin Franklin, Berlin

48149

Universitätsklinikum Münster, Münster

50924

Klinikum der Universität zu Köln, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT00404092 - Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis | Biotech Hunter | Biotech Hunter